The exciting potential of immunotherapy for cancer treatment continues its exploration and here, Drug Target Review investigates three of the latest pre-clinical developments in immuno-oncology research.
List view / Grid view
Johns Hopkins Kimmel Cancer Center
Scientists have showed that a three inhibitors (3i) cocktail could reprogramme fibroblasts to a naïve embryonic stem cell-like state and remove disease-associated epigenetic changes.
A research team have identified a protein that binds breast cancer cells together, allowing them to metastasise, which could be significant in the development of cancer therapies.
16 May 2019 | By
Researchers say they have affirmed inconsistencies in the use of a common laboratory procedure called immunohistochemical staining.
Researchers have discovered changes to five new regions in the human genome that may increase the risk of pancreatic cancer...